Reported about 1 year ago
A recent study published in JAMA Opthamology suggests that individuals taking Ozempic and Wegovy, which contain the ingredient semaglutide, may face a higher risk of developing non-arthritic anterior ischemic optic neuropathy (NAION) leading to blindness. While the study showed a significant association, further research is required to establish causality. Novo Nordisk, the manufacturer of these drugs, emphasized patient safety and the need for more investigation. NAION presents a sudden onset of blindness without known treatment, with three cases observed in one week prompting this study at Mass Eye and Ear. Researchers stress the necessity for future controlled trials to confirm the link.
Source: YAHOO